Warning Letter — Sanrace Biotechnology Co., Ltd.
The FDA issued a Warning Letter to Sanrace Biotechnology Co., Ltd. following an evaluation by the Center for Drug Evaluation and Research (CDER).
This affects Sanrace Biotechnology Co., Ltd., its manufacturing and quality departments, and potentially its downstream supply chain partners.
The issuance of a Warning Letter by CDER indicates significant deviations from Current Good Manufacturing Practice (CGMP) regulations. This may lead to regulatory hold on products, import alerts, or the withholding of new drug approvals until the identified violations are remediated and verified by the agency.
Review current manufacturing protocols against CGMP standards and ensure all facility operations are fully documented. Regulatory teams should prepare for potential import restrictions if the firm does not address the deficiencies noted by CDER.
FDA Warning Letter issued to: Sanrace Biotechnology Co., Ltd.. 10/22/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanrace-biotechnology-co-ltd-737549-10222026
Open in openFDA / FDA.gov